Generation and characterization of a new mammalian cell line continuously expressing virus-like particles of Japanese encephalitis virus for a subunit vaccine candidate

Table 1 Induction of neutralizing antibodies in mice vaccinated with the JEV-VLP antigen

Expt	Vaccine	Dosage	Neutralizing antibody titer^a		Survival rate (no. alive/total)
			Day 14	Day 28
1	BJ-ME^b (oil adjuvant)	2 μg	40	100	100% (10/10)
	BJ-ME (no adjuvant)	2 μg	70	100	100% (10/10)
	BJ-ME (no adjuvant)	4 μg	100	280	100% (10/10)
	Live vac^c	10⁶ TCID₅₀	100	120	100% (10/10)
	PBS	200 μL	<10	<10	0% (0/10)
2	BJ-ME 200 μl	3 μg	ND	160	100% (8/8)
	BJ-ME 150 μl	2.25 μg	ND	140	100% (8/8)
	BJ-ME 100 μl	1.5 μg	ND	100	87.5% (7/8)
	BJ-ME 50 μl	0.75 μg	ND	70	87.5% (7/8)
	BJ-ME 20 μl	0.3 μg	ND	40	75% (6/8)
	Live vac	10⁶ TCID₅₀	ND	160	100% (8/8)
	PBS	200 μL	ND	<10	0% (0/8)

^aTiters are expressed as the maximum serum dilution yielding a 50% plaque reduction. ^bJEV-VLP antigen. ^cLive virus vaccine (SA14-14-2 strain). ND, not determined.

ISSN: 1472-6750